ea0063gp139 | Obesity | ECE2019
Luzi Livio
, Raben Anne
, Astrup Arne
, Matejkova Erika
, Svacina Stepan
, Gnessi Lucio
, Navas-Carretero Santiago
, Martinez J Alfredo
, Greenway Frank
, Aronne Louis
, Apovian Caroline
, Kaplan Lee
, Hill James
, Fujioka Ken
, Still Christopher
, Sannino Alessandro
, Saponaro Cosimo
, Calderon Henry
, Urban Lorien
, Chiquette Elaine
, Leider Harry
, Ron Eyal
, Zohar Yishai
, Heshmati Hassan
Introduction: Identification of early responders is widely used in pharmacotherapy for weight loss to minimize unnecessary exposure to risks and unnecessary expenses. Gelesis Loss Of Weight (GLOW; NCT02307279), a multicenter, double-blind, placebo-controlled pivotal study, demonstrated that Gelesis100 offers a compelling new potential approach in the management of overweight and obesity.Objective: A post-hoc area under the curve (AUC) for the receiver op...